CIK 0001566044
- Non-accelerated filer
- Smaller reporting company
Yarrow Bioscience, Inc.
Sign in to watch- Ticker
- YARW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 453757789
- Phone
- +1 203-433-7577
- Business address
- 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
- Former names
- VYNE Therapeutics Inc., Menlo Therapeutics Inc., Menlo Therapeutics, Inc., Tigercat Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 2 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-31 | Zeronda Tyler CFO | Grant or award | +12,510 | $0.35 | $4K | 174,066 |
| 2022-05-31 | Domzalski David President and CEO | Grant or award | +11,887 | $0.35 | $4K | 1,061,636 |
| 2022-03-31 | Zeronda Tyler CFO | Shares withheld for taxes | −773 | $0.65 | $502 | 161,556 |
| 2022-03-31 | Stuart Iain Chief Scientific Officer | Shares withheld for taxes | −3,469 | $0.65 | $2K | 225,410 |
| 2022-03-31 | Harsch Mutya Chief Legal Officer and GC | Shares withheld for taxes | −3,630 | $0.65 | $2K | 234,583 |
| 2022-03-31 | Domzalski David President and CEO | Shares withheld for taxes | −23,186 | $0.65 | $15K | 1,049,749 |
| 2022-03-17 | Zeronda Tyler CFO | Grant or award | +75,000 | 162,329 | ||
| 2022-03-17 | Zeronda Tyler CFO | Grant or award · Stock Options | +75,000 | 75,000 | ||
| 2022-03-17 | Stuart Iain Chief Scientific Officer | Grant or award | +75,000 | 228,879 | ||
| 2022-03-17 | Stuart Iain Chief Scientific Officer | Grant or award · Stock Options | +75,000 | 75,000 | ||
| 2022-03-17 | Harsch Mutya Chief Legal Officer and GC | Grant or award | +75,000 | 238,213 | ||
| 2022-03-17 | Harsch Mutya Chief Legal Officer and GC | Grant or award · Stock Options | +75,000 | 75,000 | ||
| 2022-03-17 | Domzalski David President and CEO | Grant or award | +312,302 | 1,072,935 | ||
| 2022-03-17 | Domzalski David President and CEO | Grant or award · Stock Options | +312,303 | 312,303 | ||
| 2021-12-31 | Zeronda Tyler Interim CFO | Shares withheld for taxes | −206 | $1.02 | $210 | 87,329 |
| 2021-12-31 | Stuart Iain Chief Scientific Officer | Shares withheld for taxes | −1,250 | $1.02 | $1K | 153,879 |
| 2021-12-31 | Harsch Mutya Chief Legal Officer and GC | Shares withheld for taxes | −1,484 | $1.02 | $2K | 163,213 |
| 2021-12-31 | Domzalski David President and CEO | Shares withheld for taxes | −6,887 | $1.02 | $7K | 760,633 |
| 2021-11-30 | Zeronda Tyler Interim CFO | Grant or award | +4,187 | $0.88 | $4K | 87,535 |
| 2021-11-30 | LEPORE PATRICK G Director | Purchase | +12,500 | $1.02 | $13K | 62,500 |
Page 8 of 22 · 425 trades